Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Randomized, Double-blind, Placebo-controlled Study of Ursodeoxycholic Acid (UDCA) Therapy on Biomarkers of Oxidative Stress, Inflammatory and Endothelial Dysfunction in Patients With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05416580
• Other study ID #: UDCA01T2DM
• Status: Enrolling by invitation
• Phase: Phase 3
• Start date: September 12, 2022
• Est. completion date: April 2024

Study information

• Verified date: June 2022
• Source: University of Banja Luka
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of ursodeoxycholic acid (UDCA) compared to placebo on biomarkers of oxidative stress, inflammation, and endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM) who are treated with metformin but did not meet the target HbA1C < 7%.

Description:

This is a Phase 3, randomized, double-blind, placebo-controlled, evaluation of the efficacy of UDCA on oxidative stress, inflammation, and endothelial dysfunction in combination with metformin after 8 weeks in patients with T2DM who did not meet HbA1C < 7%. Study site: a single study center (Primary Health Care Institution in Banja Luka, as recruiter center) including Center for Biomedical Research, Faculty of Medicine University of Banja Luka, as reference coordinator and research center. Sample size : 60 patients, randomized in a 1:1 allocation ratio. Objectives 1. To investigate the effects of UDCA added to metformin on glycemia, HbA1C, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), lipoproteins, and body mass index. 2. To investigate whether UDCA has an impact on lipid peroxidation index, nitric oxide metabolites, hydrogen peroxide (H2O2), superoxide anion radical (O2-), and total antioxidant capacity. 3. To investigate whether UDCA has an impact on the dynamic of inflammatory markers interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and high sensitive CRP (hsCRP). 4. To investigate whether UDCA has an impact on von Willebrand factor (vWF), Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Adhesion Molecule 1 (VCAM-1), fibrinogen, homocysteine, folic acid, and vitamin D levels. Treatments arms: UDCA (1500 mg/day) + Metformin (maximum tolerated daily dose) UDCA placebo + Metformin (maximum tolerated daily dose) Treatment duration : 8 weeks Assessment - clinical and laboratory sampling: Informed consent and Screening - 7 days prior to randomization Study visits (V): V1 - Randomization and Enrollment (Baseline) V2 - 4 weeks after Baseline V3 - 8 weeks after Baseline. No interim analysis is planned. The analysis will be performed at the end of the study after data review and freezing of the database according to the intent to treat principle.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 60
• Est. completion date: April 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Signed informed consent
• Type 2 Diabetes mellitus verified at least 1 year prior to the study enrollment
• Treatment with metformin at a maximally tolerated dose (up to 2000 mg/day) in patients with an incomplete biochemical response showing HbA1c = 6,5%.
• Body mass index (BMI) corresponding to overweight and obesity (= 25 kg/m2)

Exclusion Criteria:

• Insulin treatment within 12 weeks prior to the study enrollment
• Treatment with Glucagon-like peptide 1 (GLP-1) analogs within 12 weeks prior to the study enrollment
• Systemic administration of glucocorticoids continuously for 10 days within 12 weeks prior to the study enrollment
• Prior and concomitant immunosuppressants treatment (other than glucocorticoids)
• History and current serious psychiatric disorders that could affect treatment adherence
• Co-existing uncontrolled cardiovascular disease (i.e arterial hypertension), respiratory insufficiency, acute or chronic renal failure (creatinine clearance < 60 ml/min), and liver diseases such as acute or chronic viral hepatitis, alcoholic liver disease, choledocholithiasis, autoimmune hepatitis, non-alcoholic fatty liver disease, hemochromatosis, and liver failure.
• Known history of cholecystitis
• Pregnant or lactating women
• Known hypersensitivity to UDCA, or other bile acids
• History of malignancy diagnosed or treated within 2 years (recent localized treatment of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to Screening)
• Participation in any other interventional study

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• UDCA (Ursodeoxycholic acid)
UDCA is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
• Placebo
Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
• Metformin
Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.

Locations

Country	Name	City	State
Bosnia and Herzegovina	Public Health Institution Dom zdravlja Banja Luka	Banja Luka	Republic Of Srpska

Sponsors (1)

Lead Sponsor	Collaborator
University of Banja Luka

Country where clinical trial is conducted

Bosnia and Herzegovina, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in oxidative stress biomarkers levels: superoxide dismutase (SOD), catalase, and malondialdehyde (MDA)	ELISA assay (same units)	From Baseline and after 8 weeks
Primary	Change in pro-inflammatory markers concentrations: tumor necrosis factor-a (TNF-a), and interleukin 6 (IL-6)	ELISA assay (same units)	From Baseline and after 8 weeks
Primary	Change in serum levels of homocystein	Detection by fluorescence polarization immunoassay	From Baseline and after 8 weeks
Primary	Change in serum levels of von Willebrand factor (vWF), Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Adhesion Molecule 1 (VCAM-1), and fibrinogen	ELISA assay (same units)	From Baseline and after 8 weeks
Primary	Change in serum levels of Vitamin D and Folic acid	Microparticle enzyme immunoassay (same units)	From Baseline and after 8 weeks
Primary	Change in Total antioxidant capacity (TAC) level	Results expressed in units µg/ml Trolox equivalents	From Baseline and after 8 weeks
Primary	Change in inflammation marker level: high sensitivity CRP	Turbid metric test	From Baseline and after 8 weeks
Secondary	Change in Haemoglobin A1C (HbA1C)	HbA1C level will be expressed in %	From Baseline and after 8 weeks
Secondary	Change in Total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides	Clinical biochemistry (colorimetric) tests, and results will be expressed in mmol/L (same units)	From Baseline and after 8 weeks
Secondary	Change in body weight	Weight (kg)	From Baseline and after 8 weeks

External Links

•   Bile acids signaling pathways have become attractive targets for the treatment of various metabolic diseases and metabolic syndrome opening the new potential avenue in their treatment.